KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-9966
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities ; volume:39 ; number:1 ; day:28 ; month:10 ; year:2020 ; pages:1-10 ; date:12.2020
Journal of experimental & clinical cancer research ; 39, Heft 1 (28.10.2020), 1-10, 12.2020
- Urheber
-
Luchini, Claudio
Paolino, Gaetano
Mattiolo, Paola
Piredda, Maria L.
Cavaliere, Alessandro
Gaule, Marina
Melisi, Davide
Salvia, Roberto
Malleo, Giuseppe
Shin, Jae Il
Cargnin, Sarah
Terrazzino, Salvatore
Lawlor, Rita T.
Milella, Michele
Scarpa, Aldo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13046-020-01732-6
- URN
-
urn:nbn:de:101:1-2020121207235207133564
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:39 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Luchini, Claudio
- Paolino, Gaetano
- Mattiolo, Paola
- Piredda, Maria L.
- Cavaliere, Alessandro
- Gaule, Marina
- Melisi, Davide
- Salvia, Roberto
- Malleo, Giuseppe
- Shin, Jae Il
- Cargnin, Sarah
- Terrazzino, Salvatore
- Lawlor, Rita T.
- Milella, Michele
- Scarpa, Aldo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Distinct serum metabolomics profiles associated with malignant progression in the KrasG12Dmouse model of pancreatic ductal adenocarcinoma
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
Advanced pancreatic ductal adenocarcinoma : moving forward
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Distinct serum metabolomics profiles associated with malignant progression in the KrasG12Dmouse model of pancreatic ductal adenocarcinoma
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1
Advanced pancreatic ductal adenocarcinoma : moving forward
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma
Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma
Molecular diagnosis for detecting KRAS mutation in peritoneal washing fluid of pancreatic ductal adenocarcinoma
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma
TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
Models of pancreatic ductal adenocarcinoma
Distinct serum metabolomics profiles associated with malignant progression in the KrasG12Dmouse model of pancreatic ductal adenocarcinoma
Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines
PPDPF Promotes the Development of Mutant KRAS‐Driven Pancreatic Ductal Adenocarcinoma by Regulating the GEF Activity of SOS1